NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Tenax Therapeutics, Inc. (TENX) Stock Analysis

Tenax Therapeutics, Inc. (TENX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TENX

$1.63

$0.00 (0.00%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TENX with… →

TENX Key Statistics

As of Oct 21, 2026
Trading
Open
$1.65
Previous Close
$1.63
Day's Range
1.62–1.70
52-Week Range
1.31–19.40
Volume
2.01M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.92
Valuation
Market Cap
$61.00M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.44
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.48
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$52.60M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
37.42M
1-Year Return
−77.42%
Dividend and dates
Avg Volume
5.65M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TENX closed at $1.63, −77.42% over 1 year.

Tenax Therapeutics, Inc. (TENX) has a market capitalization of $61.00M.

In fiscal 2025, TENX reported revenue of $0.00.

TENX Stock Return by Calendar Year

Tenax Therapeutics, Inc. (TENX) 10-year return: what $10,000 became

1 year
$10,000 $2,258
−77.42%
5 years
$10,000 $6
−99.94%
10 years
$10,000 $0.27
−99.997%

If you had invested $10,000 in Tenax Therapeutics, Inc. (TENX) 10 years ago, at the close on October 21, 2016, it would have been worth $0.27 at the close on October 21, 2026: −99.997% in total, −65.04% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−86.63%
2025+96.93%
2024−71.86%
2023−87.61%
2022−89.33%
2021−44.09%
2020+31.91%
2019+16.53%
2018−87.65%
2017−74.87%
2016 (partial year)−21.69%

As of October 21, 2026.

TENX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$52.60M—
2024$0.00−$17.60M—
2023$0.00−$7.71M—
2022$0.00−$11.05M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$56.39M−$52.60M—
2024$0.00—−$19.49M−$17.60M—
2023$0.00—−$8.23M−$7.71M—
2022$0.00—−$11.05M−$11.05M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Tenax Therapeutics, Inc. (TENX) at $61.00M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 14.

The 52-week range on file runs from $1.31 to $19.40. TENX last closed at $1.63 on October 21, 2026. The close was unchanged from the previous session. The latest close sits 24.43% above that 52-week low.

Financial Health

In fiscal 2025, Tenax Therapeutics, Inc. reported revenue of $0.00. The same year closed with a net loss of $52.60M. Earnings per share on a trailing basis come to −1.48.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.44.

Beta against the wider market is reported at 0.92. Daily returns over the trailing 10 years annualize to a volatility of 147.69%. The trailing one-year total return is −77.42%. Across 10 years the annualized return works out at −65.04%.

Growth & Income

No dividend is on file for TENX.

The strongest complete calendar year on file is 2025 at +96.93%; the weakest is 2022 at −89.33%. Of the 9 complete calendar years on file, 3 finished higher. So far in 2026 the total return is −86.63%.

Peer Comparison

Tenax Therapeutics, Inc. (TENX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Tenax Therapeutics, Inc. TENX $61.00M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Tenax Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.

Visit website →